ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – IMVT, HSACU, HSAC, HSACW
March 03, 2021 15:26 ET
|
The Rosen Law Firm PA
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
October 25, 2017 08:00 ET
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...